Defective Sequencing Reagents to Cost Illumina up to $23M in 2009; Company Says Problem is Solved

The faulty reagent kits, a problem that Illumina said it first discovered in September and has since rectified, cost the company up to $8 million in lost revenue in the third quarter. The issue is expected to decrease revenues in the fourth quarter by up to $15 million.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.